openPR Logo
Press release

Primary Biliary Cholangitis Therapeutics Market Insights : Increase in Research and Development of Primary Biliary Cholangitis Therapeutics is Boosting the Market to Propel USD 1.4 Billion Revenue by 2032

04-18-2024 11:00 AM CET | Health & Medicine

Press release from: Allied Market Research

Primary Biliary Cholangitis Therapeutics Market Insights :

Allied Market Research published a report, titled, "Primary Biliary Cholangitis Therapeutics Market by Drug Type (Primary Drug and Secondary Drug), and Distribution Channel (Hospital Pharmacies, Drugs Stores and Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032" According to the report, the global primary biliary cholangitis therapeutics industry generated $0.68 billion in 2022 and is anticipated to generate $1.36 billion by 2032, witnessing a CAGR of 7.1% from 2023 to 2032.

The growth of the global primary biliary cholangitis therapeutics market is driven by increased awareness of the disease in developing countries, rising demand for corresponding treatments, and expanded research and development efforts. However, challenges such as delayed diagnosis and limited treatment options impede market growth. Conversely, opportunities for market expansion are anticipated through the adoption of key strategies by major industry players and the escalation of clinical trials investigating drugs for primary biliary cholangitis treatment.

๐‘๐ž๐ช๐ฎ๐ž๐ฌ๐ญ ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‚๐จ๐ฉ๐ฒ ๐จ๐Ÿ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/A108539

The primary drug segment dominated the global primary biliary cholangitis therapeutics market in 2022, representing over four-fifths of the revenue. It is expected to maintain its leading position throughout the forecast period due to the increasing adoption of primary drugs for treating primary biliary cholangitis (PBC). This segment is also projected to exhibit the highest compound annual growth rate (CAGR) of 7.3% from 2023 to 2032. This growth can be attributed to the intensified research and development efforts focused on primary drugs and their high effectiveness against PBC.

In 2022, North America emerged as the region with the highest revenue share in the global primary biliary cholangitis therapeutics market, capturing over two-fifths of the market revenue. This was attributed to its robust healthcare infrastructure, the presence of key industry players, and an increase in healthcare spending. However, the Asia-Pacific region is anticipated to experience the fastest compound annual growth rate (CAGR) of 8.5% from 2023 to 2032. It is expected to lead the market during the forecast period due to a surge in primary biliary cholangitis cases, unmet medical needs, and a large population base.

๐‹๐ž๐š๐๐ข๐ง๐  ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐๐ฅ๐š๐ฒ๐ž๐ซ๐ฌ: -
ABC Farmaceutici S.p.a.
Alkem Laboratories Limited
AMAGEN INDIA LIFE SCIENCES
GENFIT
Intercept Pharmaceuticals, Inc.
Ipsen Pharma
Leeford Healthcare Ltd
Lupin
Sun Pharmaceutical Industries Ltd.
Zydus Lifesciences Limited

The report provides a detailed analysis of these key players in the global primary biliary cholangitis therapeutics market. These players have adopted different strategies such as acquisition, product launch, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

๐‘๐ž๐œ๐ž๐ง๐ญ ๐€๐ ๐ซ๐ž๐ž๐ฆ๐ž๐ง๐ญ ๐ข๐ง ๐ญ๐ก๐ž ๐๐ซ๐ข๐ฆ๐š๐ซ๐ฒ ๐๐ข๐ฅ๐ข๐š๐ซ๐ฒ ๐‚๐ก๐จ๐ฅ๐š๐ง๐ ๐ข๐ญ๐ข๐ฌ ๐“๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ๐ฌ ๐Œ๐š๐ซ๐ค๐ž๐ญ

In May 2022, Intercept Pharmaceuticals, Inc. announced that it has entered into an agreement to sell to Advanz Pharma, a pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, certain foreign subsidiaries and rights regarding Intercept's international operations, including a license to commercialize Ocaliva (obeticholic acid) outside of the U.S.

๐’๐ฉ๐ž๐š๐ค ๐ญ๐จ ๐€๐ง๐š๐ฅ๐ฒ๐ฌ๐ญ-https://www.alliedmarketresearch.com/connect-to-analyst/A108539

๐‘๐ž๐œ๐ž๐ง๐ญ ๐๐ซ๐จ๐๐ฎ๐œ๐ญ ๐€๐ฉ๐ฉ๐ซ๐จ๐ฏ๐š๐ฅ ๐ข๐ง ๐ญ๐ก๐ž ๐๐ซ๐ข๐ฆ๐š๐ซ๐ฒ ๐๐ข๐ฅ๐ข๐š๐ซ๐ฒ ๐‚๐ก๐จ๐ฅ๐š๐ง๐ ๐ข๐ญ๐ข๐ฌ ๐“๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ๐ฌ ๐Œ๐š๐ซ๐ค๐ž๐ญ

Global pharma major Lupin Limited (Lupin) announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application for Obeticholic Acid Tablets, 5mg and 10mg, a generic equivalent of Ocaliva Tablets, 5 mg, and 10 mg, of Intercept Pharmaceuticals, Inc. This product will be manufactured at Lupin's Nagpur facility in India.

๐‘๐ž๐œ๐ž๐ง๐ญ ๐๐š๐ซ๐ญ๐ง๐ž๐ซ๐ฌ๐ก๐ข๐ฉ ๐ข๐ง ๐ญ๐ก๐ž ๐๐ซ๐ข๐ฆ๐š๐ซ๐ฒ ๐๐ข๐ฅ๐ข๐š๐ซ๐ฒ ๐‚๐ก๐จ๐ฅ๐š๐ง๐ ๐ข๐ญ๐ข๐ฌ ๐“๐ก๐ž๐ซ๐š๐ฉ๐ž๐ฎ๐ญ๐ข๐œ๐ฌ ๐Œ๐š๐ซ๐ค๐ž๐ญ

In December 2021, Ipsen and Genfit have entered a long-term strategic partnership in which Genfit has given Ipsen exclusive worldwide license to develop, manufacture, and commercialize its experimental late-stage treatment elafibranor, for people living with primary biliary cholangitis. The partnership also gives Ipsen access to future clinical programs led by Genfit and combines scientific expertise and proprietary technologies in liver disease of Genfit with development and commercialization capabilities of Ipsen.

๐Š๐ž๐ฒ ๐Ÿ๐ข๐ง๐๐ข๐ง๐ ๐ฌ ๐จ๐Ÿ ๐ญ๐ก๐ž ๐ฌ๐ญ๐ฎ๐๐ฒ

On the basis of drug type, the primary drug segment held the largest share in the primary biliary cholangitis therapeutics market analysis in 2022.

On the basis of distribution channel, the drugs stores and retail pharmacies dominated the market in 2022.

On the basis of region, Asia-Pacific is expected to witness the highest CAGR during the forecast period.

๐Š๐ง๐จ๐ฐ ๐Œ๐จ๐ซ๐ž- https://www.alliedmarketresearch.com/primary-biliary-cholangitis-pbc-therapeutics-market-A108539

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Biliary Cholangitis Therapeutics Market Insights : Increase in Research and Development of Primary Biliary Cholangitis Therapeutics is Boosting the Market to Propel USD 1.4 Billion Revenue by 2032 here

News-ID: 3468507 • Views: โ€ฆ

More Releases from Allied Market Research

Global Urinary Drainage Bags Market: Trends, Growth, and Insights to 2031
Global Urinary Drainage Bags Market: Trends, Growth, and Insights to 2031
The global urinary drainage bags market is experiencing robust growth, with its market size valued at $1.4billion in 2021 and projected to reach $2billion by 2031. This expansion represents a compound annual growth rate (CAGR) of 3.8% from 2021 to 2031, highlighting the increasing demand for these essential medical devices. Get a Sample Copy of this Report: https://www.alliedmarketresearch.com/request-sample/A17529 What Are Urinary Drainage Bags? Urinary drainage bags are specialized medical devices designed to collectโ€ฆ
Cream Powder Market to Reach $8.9 Billion by 2031 with 6.4% CAGR
Cream Powder Market to Reach $8.9 Billion by 2031 with 6.4% CAGR
The global cream powder industry was estimated at $4.8 billion in 2021 and is expected to hit $8.9 billion by 2031, registering a CAGR of 6.4% from 2022 to 2031. The cream powder market is experiencing growth due to various factors, including the increasing popularity of bakeries and HoReCa (hotels, restaurants, and cafes) and rising consumer demand for natural products. The dairy-based segment is a significant contributor to the market's growthโ€ฆ
Micro Drone Market Valued at $6.71 Billion in 2020, Expected to Reach $28.91 Billion by 2030; Growing at a CAGR of 17.2%
Micro Drone Market Valued at $6.71 Billion in 2020, Expected to Reach $28.91 Bil โ€ฆ
The global micro drone industry generated $6.71 billion in 2020, and is expected to reach $28.91 billion in 2030, witnessing a CAGR of 17.2% from 2021 to 2030. The report provides an extensive analysis of changing market dynamics, top segments, top investment pockets, regional landscape, value chain, and competitive scenario. Increased operational efficiency and rise in demand for improved surveillance drive the growth of the global micro drone market. However, strictโ€ฆ
Microwavable Foods Market to reach $230.93 billion by 2031, growing at a CAGR of 5.6%
Microwavable Foods Market to reach $230.93 billion by 2031, growing at a CAGR of โ€ฆ
The global microwaveable foods industry was accounted for $120.45 billion in 2020, and is expected to reach $230.93 billion by 2031, growing at a CAGR of 5.6% from 2022 to 2031. Rise in popularity of fast-food restaurants and large population base coupled with increase in number of quick-service restaurants drive the global microwaveable foods market. However, lack of awareness about microwavable foods hinders the market growth. On the contrary, rise inโ€ฆ

All 5 Releases


More Releases for Pharma

Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M โ€ฆ
๐”๐’๐€, ๐๐ž๐ฐ ๐‰๐ž๐ซ๐ฌ๐ž๐ฒ- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USDย 22.32ย Billion by 2024. The valuation is expected to reach USDย 47.79ย Billion by 2031. The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of theโ€ฆ
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi โ€ฆ
๐”๐’๐€, ๐๐ž๐ฐ ๐‰๐ž๐ซ๐ฌ๐ž๐ฒ- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasingโ€ฆ
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi โ€ฆ
๐”๐’๐€, ๐๐ž๐ฐ ๐‰๐ž๐ซ๐ฌ๐ž๐ฒ- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031. The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. Asโ€ฆ
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh โ€ฆ
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of theโ€ฆ
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, โ€ฆ
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis. Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382 The Indomethacin Global Market Research Report provides close monitoringโ€ฆ
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 โ€ฆ
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024. Global Roxatidine Market overview: Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about theโ€ฆ